- Conference runs November 27–28 at the Hilton Bogotá Corferias, continuing ISSCA’s expansion of physician education throughout Latin America
- Program targets more than 250 physician attendees across flagship and peptide-medicine certification tracks
- Event complements Cellgenic’s parallel commercial expansion into Colombia
FOR IMMEDIATE RELEASE
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 128, its conference in Bogotá, Colombia, taking place November 27–28 at the Hilton Bogotá Corferias.
The Bogotá conference continues ISSCA’s ongoing expansion of physician education throughout Latin America, with a program built around the organization’s flagship and peptide-medicine certification tracks. Confirmed faculty and full workshop programming will be published as the event date approaches.
The event runs alongside Cellgenic’s operational expansion into Colombia, reinforcing ISSCA and Cellgenic’s coordinated approach to entering new Latin American markets through both education and commercial channels.
“Bogotá gives ISSCA a direct connection to Colombia’s physician community right as Cellgenic is building out commercial operations there too,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “That kind of coordination is exactly the model we want to replicate.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
